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Abstract 
Background: There is lack of outcome data for bacteraemic patients on specialist 
renal units. We described demographic, clinical, microbiological data and outcomes 
for bacteraemic adult renal transplant and non-transplant recipients at a London 
Teaching Hospital. We also assessed the appropriateness of empirical antimicrobial 
policy. 
Methods: From December 2012 - November 2013, demographic, clinical and 
microbiological data were collected on consecutive patients with bacteraemia on a 
specialist UK renal unit. Empirical anti-microbial policy, based upon sites of 
infection, was piperacillin / tazobactam or meropenem for graft pyelonephritis, and 
vancomycin and gentamicin for suspected central venous catheter (CVC) associated 
infection. 
Results: 113 bacteraemic episodes occurred in 83 patients. One patient had two 
bacteraemic episodes, one on haemodialysis and another after transplantation so 
appear in both groups. In the non-transplant group, 30-day mortality was 4/59 
(6.8%), more than the renal transplant group, 0/25 (0%). While graft pyelonephritis 
was the predominant cause of bacteraemic episodes in renal transplant patients, 
25/36 (69.4%), there were a variety of other causes in the non-transplant group 
including uncomplicated line associated bacteraemia, 36/77 (46.8%), complicated line 
associated bacteraemia, 11/77 (14.3%) and bacteraemia unrelated to vascular access 
sites 19/77 (24.7%). Overall, commonest isolates were MSSA, 20/77 (26.3%), and E. 
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coli 28/113 (24.8%). There were no MRSA isolates and, among Enterobacteriaceae, 
15/57 (26.3%) were ESBL producers.  
Conclusions: Death only occurred in the non-transplant renal group. Empirical 
antibiotic treatment with either piperacillin/tazobactam and amikacin, or 
meropenem was appropriate for renal transplant recipients as most bacteraemic 
episodes were secondary to graft pyelonephritis. Vancomycin and gentamicin was 
appropriate empirical antibiotic treatment for non-transplant patients with CVC 
associated infections, but not optimal for other sites of infection.       
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Introduction 
Compared to other speciality inpatients, renal patients are more prone to 
bacteraemia and have higher infection related mortality(1,2). This is a consequence of 
medical devices (which predispose to infection), co-morbidities (which adversely 
affect outcome) and immunosuppression in renal transplant patients. Haemodialysis 
patients often have difficult vascular access and dialysis is only feasible via a central 
venous catheter (CVC), increasing the risk of infection six fold compared to patients 
with an arteriovenous fistula(3,4). Early renal transplant patients require urinary 
catheters and ureteric stents, increasing the risk of graft pyelonephritis, and late 
renal transplant patients are prone to urosepsis because of previous surgery, 
structural anomaly and continued immunosuppression(5). Although patients 
receiving renal replacement therapy may have an infection related mortality rate up 
to 25% (Renal Registry Report 2005)(6) there is limited outcome data for bacteraemic 
patients on specialist renal units and a direct comparison between bacteraemic renal 
transplant and non-transplant recipients has never been made.  
The aim of this study was to describe patient demographic, microbiological and 
clinical outcomes, in consecutive patients on a specialist renal unit with bacteraemia, 
and 30-day outcomes for renal transplant and non-transplant recipients. Based on 
the organisms isolated, susceptibility profiles and sites of infection, we also assessed 
the appropriateness of empirical antibiotic policy. 
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Methods 
Study setting 
The study was undertaken at The Renal Centre at The Royal London Hospital 
(RLH), a 900 bedded acute major hospital and part of Barts Health NHS Trust. The 
Renal Centre forms the hub of nephrology services in North East London with 
satellite dialysis units at Queens Hospital, King George Hospital, Newham General 
University Hospital and Whipps Cross University Hospital.  It serves an elderly and 
ethnically diverse population in an area of East London, extending into Essex.  
The Renal Centre comprises of both inpatient and outpatient areas.  Within the 
inpatient area there are two wards with 62 beds, including a six bedded renal high 
dependency unit and a six bedded renal surgical unit.  Within the outpatient area, 
there is a Renal Assessment Unit and a 70 station dialysis unit (including a Blood 
Borne Virus isolation area).  The unit has provided services for patients with chronic 
kidney disease on haemodialysis and peritoneal dialysis as well as those who have 
undergone kidney transplantation. The unit also supports patients suitable for a 
‘Home Haemodialysis’ service.  
Study population 
The renal unit provides services for the following groups of patients with renal 
disease; 975 patients on haemodialysis, 219 on peritoneal dialysis, 1,034 renal 
transplant recipients, 2,780 general nephrology patients and 392 low clearance 
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patients (ie. those with an eGFR<20ml/min). From December 2012 to November 
2013, we prospectively included consecutive in-patients with bacteraemia.  
Definitions 
Bacteraemia was considered significant if there was a blood culture isolate obtained 
from a patient with a compatible clinical syndrome that was unlikely to be a skin or 
environmental contaminant. This was based upon the patient’s history, examination, 
response to anti-microbial therapy and bacterial isolates from other body sites(7).  
Community and hospital-acquired bacteraemia were defined as a positive blood 
culture obtained either 48 hours before or after admission to hospital. Health care 
associated bacteraemia, a subset of community-acquired infection, was defined as 
bacteraemia in patients who had resided in a nursing home or long- term facility 30 
days prior to the bacteraemia episode, had been hospitalised for 4 hours or longer in 
the 90 days before bacteraemia or had attended a hospital or dialysis clinic and 
received therapy in the 30 days before bacteraemia. Specialities at the time of 
bacteraemia were categorised as Medicine, Surgery, Critical Care, Obstetrics and 
Gynaecology, Neonatology and Paediatrics. The medical speciality was subdivided 
into renal and non-renal medical patients. Renal patients were further categorised 
into non-transplant renal patients, early renal transplant patients (within 6 weeks of 
transplantation) and late renal transplant patients (6 weeks post transplantation). 
The Centres for Disease Control and Prevention definitions were used to define the 
sites of infection(8).  For CVC associated infection, this was defined as evidence of 
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infection (erythema, induration or pus) at the CVC exit site or isolation of the same 
organism from the line tip or blood. Catheter associated UTIs were defined as 
infection in patients with indwelling urethral or suprapubic catheters, or patients 
who intermittently self-catheterised, in the presence of symptoms or signs 
compatible with a UTI where no other source was identified. Bacteraemia in patients 
with an unknown source were classified as undefined. Any component of an 
antibiotic regimen, definitive or empirical, used to treat an infection to which the 
organism was susceptible in vitro was defined as appropriate treatment. Day one 
was defined as the day on which a significant blood culture was obtained from the 
patient.  
Empirical antibiotic policy 
For renal transplant recipients with presumed graft pyelonephritis, intravenous 
piperacillin/tazobactam and amikacin, with doses adjusted for renal function, were 
administered concurrently. For patients with severe sepsis, defined as a Pitt score > 
2, or previous infection or colonisation with an extended spectrum beta-lactamase 
(ESBL) producing Enterobacteriaceae, intravenous meropenem was first line 
empirical treatment.  
For patients receiving haemodialysis, and where the site of infection was thought to 
be CVC associated, empirical intravenous vancomycin and gentamicin, renally dose 
adjusted, were administered.  For other sites of infection, doctors were asked to refer 
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to the Barts Health NHS antimicrobial guideline for renal transplant recipients, the 
acute general infection guideline or seek microbiological advice. 
Data collection 
From 1’st December 2012 to 30’th November 2013, consecutive adult inpatients with 
bacteraemia on the specialist renal unit based at the RLH were studied. Physicians 
attending patients who presented with symptoms and signs suggestive of sepsis 
were encouraged to obtain blood cultures before the administration of empirical 
antibiotics. One Consultant Microbiologists, aided by several specialist training 
registrars, reviewed patients’ case notes within 72 hours of laboratory confirmation 
of a positive blood culture result. In all RLH inpatients who developed bacteraemia, 
demographic data, speciality at the time of the bacteraemia, site of infection, the 
organism isolated, susceptibility profile, delay in appropriate treatment, Pitt 
bacteraemia score, Charlson Co-morbidity Index (CCI)(9) and 7 and 30-day outcomes 
were recorded. The Pitt Bacteraemia Score is a validated scoring system used to 
quantify severity of infection. It is based on the patient’s mental status, the need for 
mechanical ventilation, temperature and blood pressure. The highest score, 48 hours 
before or on the day of the first positive blood culture, was recorded. 
Patients were empirically treated according to the local hospital guidelines based on 
site of infection. Once the susceptibility profiles of the bacterial isolate were known, 
the antibiotic treatment regimens were altered to narrow spectrum agents and time 
to administration of effective treatment recorded. Patients were followed until 
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discharge from hospital, recovery or death. Outcomes were recorded as survived or 
died at 7 or 30 days from blood culture ascertainment. It was assumed that patients 
who were discharged before the 7th or 30th day survived. 
Microbiology data 
Blood cultures were analysed using an automated system BacT/ALERT3D 
(bioMerieux, Mary l’Etoile, France). Isolates were identified using either the VITEK 
MS system (bioMerieux, Mary l’Etoile, France, database v2.0) or Bruker Biotyper 
(Bruker Daltonic, Leipzig, Germany, software version 3.0) MALDI-TOF MS systems 
according to the manufacturer’s instructions and the laboratory standard operating 
procedures. Susceptibility testing was performed on the Microscan walkAway 
system (Siemans Healthcare Diagnostics, Deerfield, II, US) a minimum inhibitory 
concentration based susceptibility testing platform. 
Data analysis 
Quantitative data are presented as numbers with percentages. Continuous data are 
presented as mean and standard deviation (SD) or mean and 95% confidence 
interval (CI). 
Clinical Governance  
This study was registered as an audit and approved by the clinical governance 
committee of Barts Health NHS Trust. Ethical approval was not required. 
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Results: 
Bacteraemic episodes 
From 1’st December 2012 to 30’th November 2013, there were 594 bacteraemic 
episodes among 513 patients at the Royal London Hospital.  413 (69.5%) occurred in 
medical patients, 101 (17.0%) in surgical patients and 80 (13.5%) in other patients. 
Overall, bacteraemiac episodes associated with 83 adult renal patients accounted for 
113/594 (19.0%) hospital episodes and 113 (27.4%) episodes in adult medical patients.   
Patient categories and vascular access devices  
One patient had two bacteraemic episodes, one whilst on haemodialysis and another 
6 weeks after renal transplantation. We report these two episodes separately so the 
patient appears in both groups. Among renal patients with bacteraemic episodes, 59 
(70.2%) were receiving haemodialysis, 23 (27.4%) were late renal transplant 
recipients and only 2 (2.4%) were early renal transplant patients, so we reported 
early and late renal transplant groups together. Among the 59 patients on 
haemodialysis, 43 (72.9%) received treatment via a tunnelled haemodialysis line, 9 
(15.3%) via an ateriovenous fistula (AVF), 1 (1.7%) via a polytetrafluoroethylene 
graft and 3 (5.1%) via a vascath (temporary dialysis access). There were 3 other 
patients, 2 on peritoneal dialysis and 1 general nephrology patient. 
Renal transplant patients  
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The majority of bacteraemic episodes for patients with renal trasplant were hospital-
acquired or health-care associated infections, 31/36 (86.1%) (table 1). The commonest 
site of infection was graft pyelonephritis, 25/36 (69.4%) (table 1). A small proportion 
of episodes were severe infections, defined as a Pitt score > 2, 3/36 (8.3%), and the 
majority of patients received an appropriate antibiotic within 6 hours of blood 
culture ascertainment, 29/36 (80.6%) (table 1). No renal transplant patient died 
within 30 days of a bacteraemic episode (table 1). 
The commonest organisms causing bacteraemia in renal transplant patients were E. 
coli, 16/36 (44.4%) or K. pneumoniae, 12/36 (33.3%) (table 1). Among all 29 
Enterobacteriaceae, there were 8 (27.6%) extended beta-lactamase producers (ESBLs) 
but no carbapenemase resistant organisms (CROs). 11 (37.9%) were resistant to co-
amoxiclav, 9 (31.0%) were resistant to piperacillin / tazobactam and 6 (20.7%) were 
resistant to gentamicin. There was no resistance to amikacin.  
Non-transplant renal patients 
The majority of bacteraemic episodes, 77, occurred in 59 haemodialysis patients 
(table 1). Most infections were health-care associated 66/77 (85.7%) and 9/77 (11.7%) 
were severe (Pitt score >2) (table 1). Most sites of infection were related to vascular 
access sites and were uncomplicated; 36/77 (46.8%) or complicated by metastatic 
infection including endocarditis, vertebral osteomyelitis and peripheral joint 
infection 11/77 (14.3%) (table 1). There were 19/77 (24.7%) non-vascular access types 
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of infection, predominantly UTIs, 9/19 (47.4%), but infection at other sites also 
occurred (table 1). 
38/77 (49.4%) were Gram-positive, 33/77 (42.8%) were Gram-negative and 6/77 (7.8%) 
were Candida infections (table 1). The commonest organism isolated were MSSA, 
20/77 (26.3%), E. coli, 12/77 (15.8%) and K. pneumoniae 7/77 (9.6%) (table 1). Among 
the 28 Enterobacteriaceae there were 7 (25.0%) ESBL producers and no CROs.  
Eleven (39.3%) were co-amoxiclav resistant, 7 (25.0%) piperacillin / tazobactam 
resistant, 5 (17.9%) resistant to gentamicin and 2 (7.1%) resistant to amikacin (table 
1). Among the Gram-positive isolates there were no MRSA isolates. Most patients 
received appropriate empirical treatment within 6 hours of a blood culture, 53/77 
(68.8%) (table 1).  
30-day mortality  
There were no deaths at 7-days but 4/59 (6.8%) at 30-days, all non-transplant renal 
patients; 3 haemodialysis patients and 1 peritoneal dialysis patient (table 1). The 
organisms isolated were 3 Enterobacteriaceae (K. pneumoniae, E. coli and P. 
mirabilis) and 1 vancomycin resistant enterococcus (VRE). All were uncomplicated 
infections; 2 non-catheter associated UTIs, 1 CVC infection and 1 not defined.   
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Discussion 
A comparison between solid organ transplant and non-solid organ transplant 
bacteraemic patients has previously been made but not exclusively for renal 
patients(10). This case-control study, which included renal, liver, kidney/pancreas, 
small bowel/liver and heart/lung transplant recipients demonstrated a significant 
survival advantage for transplant patients compared to non-transplant patients. Our 
study is the first to show outcomes in consecutive adult bacteraemic renal patients 
who were either renal transplant or non-transplant recipients. At 30-days deaths 
only occurred in the non-transplant group and it is unclear whether these 
uncomplicated infections were their primary cause of death. 
 
In renal transplant patients, bacteraemia related mortality ranges from 3-16.7%(2,11). 
While most studies report Gram-negative organisms as the commonest causes of 
bacteraemia and the urinary tract as the commonest site, there is lack of 
contemporary susceptibility data. One paper found P. aeruginosa to be the 
commonest blood culture isolate with a cure rate of 55%(12). Most investigators, like 
us, found E. coli and K. pneumoniae to be the commonest isolates with cure rates 
approaching 100%(2,5). In our study we demonstrated that most bacteraemic 
infections were caused by graft pyelonephritis and were not associated with death 
due to antimicrobial failure. For graft pyelonephritis, it therefore appears 
appropriate to use piperacillin / tazobactam and amikacin as empirical treatment 
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and meropenem only when treating severe infection, or when patients are known to 
be colonised or infected with ESBL producing Enterobacteriaceae. Outcomes in the 
renal transplant cohort were excellent, suggesting that no modification to our 
empirical antimicrobial policy is required.  
 
Worldwide, there are a limited number of studies of bacteraemia in non-transplant 
renal patients. In a retrospective, 16-year cohort study of bacteraemic patients 
undergoing haemodialysis (71 patients and 85 bacteraemic episodes)(13), two-thirds’s 
of episodes were caused by Gram-positive organisms and, overall, mortality was 
15%, highest amongst those with shock and infective endocarditis. Other studies 
focus upon specific categories of infection so mortality rates are not directly 
comparable to our findings. In a Scottish study of 84 patients on haemodialysis with 
Gram-negative bacteraemia(14), sources identified were sites unrelated to vascular 
access such as urinary and biliary tract, a finding similar to ours. A variety of 
predominantly sensitive organisms were isolated but, despite this, mortality was 
24/84 (25.3%). In a Danish cohort study(15), patients with S. aureus bacteraemia on 
haemodialysis had a 90-day case fatality of 18.2% and in a larger cohort of 3359 
haemodialysis-dependent patients(16), mortality at 12 weeks was 20%. Two studies 
describe sites of metastatic infection following Gram-positive bacteraemia such as 
infective endocarditis, vertebral osteomyelitis, septic arthritis of peripheral joints and 
endophthalmitis(12,17). Some studies describe an association between mortality and co-
morbidities and severity of infection(18) and it is not surprising that we found higher 
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mortality in non-transplant renal patients, an older population with more co-
morbidities, compared to renal transplant recipients.   
 
The recent Scottish paper also provides information on susceptibility profiles and 
assessed the appropriateness of empirical antimicrobial policy for patients on 
haemodialysis(14). Compared to this study, we found higher rates of resistance 
among Gram-negative isolates in non-transplant renal patients (eg. gentamicin 
20.7% vs 17.9% and piperacillin / tazobactam 31.0% vs 25.0%) and an unexpectedly 
high rate of co-amoxiclav resistance, 39.3%. We also found no resistance to 
meropenem and amikacin. Vancomycin and gentamicin proved effective empirical 
treatment for complicated and uncomplicated line associated infection, but less 
effective for other sites of infection due to high levels of gentamicin resistance. 
Amakicin would have been more appropriate treatment (resistance was 7.1%) but 
empirical treatment could have been further optimised by careful determination of 
site of infection, rather than assuming all infections were vascular access associated. 
 
There were limitations to this paper. The number of deaths was small, so we were 
unable to perform multivariate analysis and adjust for host and other factors when 
comparing outcomes in renal transplant and non-transplant recipients. We did, 
however, demonstrate significant differences in age and co-morbidity which may 
partly explain the differences in survival between the two groups.  
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In summary, the majority of bacteraemic episodes in renal transplant patients 
occurred in late transplant recipients and the commonest site of infection was graft 
pyelonephritis. There were no associated deaths and the antibiotic policy, based on 
likely isolates and susceptibility profiles, was appropriate. For non-transplant 
patients, predominantly on haemodialysis, there were a variety of sites of infection 
which included CVC associated infections (uncomplicated or complicated) and other 
sites unrelated to vascular access. Although mortality at 30-days was < 7%, these 
patients need to be properly assessed and investigated as vancomycin and 
gentamicin is not always appropriate treatment for non-vascular access site 
infections. Younger age and fewer co-morbidities may partly explain better 
outcomes in renal transplant recipients. Overall, compared to other renal units with 
published bacteraemia data, our unit had exceptionally good outcomes.  
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Table 1: Demographic, Microbiological and Clinical Outcome data of 83 renal 
patients with 113 bacteraemia episodes 
 Transplant Non-
Transplant  
Patients 25 59 
Bacteraemic episodes 36 77 
Age*, n (%) 
16-30 
31-50 
51-70 
>70 
 
2 (8.0) 
9 (36.0) 
13 (52.0) 
1 (4.0) 
 
4 (6.8) 
16 (27.1) 
28 (47.5) 
11 (18.6) 
Gender*, n (%) 
Male 
Female 
 
11 (44.0) 
14 (56.0) 
 
35 (59.3) 
24 (40.7) 
Pitt score, n (%) 
0 
>0 and ≤2 
>2 
 
17 (47.2) 
16 (44.4) 
3 (8.3) 
 
44 (57.1) 
24 (31.2) 
9 (11.7) 
CCI, n (%) 
0 
>0 and ≤2 
>2 
 
2 (5.6) 
23 (63.9) 
11 (30.6) 
 
2 (2.6) 
24 (31.2) 
51 (66.2) 
Where infection was acquired, n (%) 
CAI 
HAI 
HCAI 
 
5 (13.9) 
12 (33.3) 
19 (52.8) 
 
1 (1.3) 
10 (13.0) 
66 (85.7) 
Organism, n (%) 
MSSA 
E coli 
K pneumonia 
E faecalis 
Candida 
CoNS 
E cloacae 
P aeruginosa 
P mirabilis 
S marcescens 
VRE 
E faecium 
S. milleri 
S pneumoniae 
Viridans Streptococcus 
B fragilis 
 
Missing 
 
1 (2.8) 
16 (44.4) 
12 (33.3) 
1 (2.8) 
2 (5.6) 
0 
0 
0 
1 (2.8) 
0 
1 (2.8) 
2 (5.6) 
0 
0 
0 
  0 
 
0 
 
20 (26.0) 
12 (15.4) 
7 (9.1) 
7 (9.1) 
6 (7.8) 
4 (5.2) 
4 (5.2) 
4 (5.2) 
3 (3.9) 
2 (2.6) 
2 (2.6) 
1 (1.3) 
1 (1.3) 
1 (1.3) 
1 (1.3) 
1 (1.3) 
 
1 (1.3) 
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 Transplant Non-
Transplant  
Patients 25 59 
Bacteraemic episodes 36 77 
Sites of infection, n (%) 
   Fistula 
   Uncomplicated line associated 
   Complicated (line associated)  
        Infective endocarditis (native) 
        PPM endocarditis  
        Vertebral column 
        Peripheral joint (native) 
   Other 
        UTI (non-catheter associated) 
        UTI (catheter associated) 
        Liver abscess 
        Renal abscess 
        Tooth abscess 
        LRT (non-ventilator associated)  
        Skin and soft tissue infection 
        GI tract 
        Biliary tract 
        Osteomyelitis (contiguous) 
   Not defined 
 
0 
1 (2.8) 
0 
0 
0 
0 
0 
31 (86.1%) 
25 (69.4) 
4 (11.1) 
0 
0 
0 
0 
2 (5.6) 
0 
0 
0 
4 (11.1) 
 
1 (1.3) 
36 (46.8) 
11 (14.3) 
5 (6.5) 
2 (2.6) 
2 (2.6) 
2 (2.6) 
19 (24.6) 
7 (9.1) 
2 (2.6) 
2 (2.6) 
1 (1.3) 
1 (1.3) 
1 (1.3) 
2 (2.6) 
1 (1.3) 
1 (1.3) 
1 (1.3) 
10 (13.0) 
Time from blood culture ascertainment to 
administration of appropriate antibiotics (hours), 
n (%) 
<6 
<24 
<48 
<72 
>72 
 
 
 
29 (80.6) 
4 (11.1) 
1 (2.8) 
1 (2.8) 
1 (2.8) 
 
 
 
53 (68.8) 
11 (14.3) 
8 (10.4) 
3 (3.9) 
2 (2.6) 
Mortality*, (%) 
7 days 
30 days 
 
0 
0 
 
0 
4 (6.8) 
CCI: Charlson Co-morbidity Index; CAI: community acquired infection; HAI: Hospital acquired 
infection; HCAI: Heath care association infection; PPM: permanent pacemaker; UTI: urinary tract 
infection; LRT: lower respiratory tract; GI: gastrointestinal 
One patient had a bacteraemic episode while receiving haemodialysis and another > 6 weeks after 
renal transplantation so appear in both groups 
*patient specific variables so reported as a percentage of patients  
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